Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13566481 | 0.83 | GLP1R (0.58) | GLP1RTLR2ADRA1AMEN1KMT2A | |
| SCHEMBL19465297 | 0.83 | GLP1R (0.58) | GLP1RTLR2ADRA1AMEN1KMT2A | |
| SCHEMBL12673824 | 0.81 | ADRA1A (0.61) | GLP1RADRA1AEPHX2 | |
| SCHEMBL14550117 | 0.78 | GLP1R (0.49) | GLP1RTLR2NMT2NMT1 | |
| SCHEMBL26257859 | 0.78 | GLP1R (0.63) | GLP1RNMT2NMT1EPHX2EPOR | |
| SCHEMBL11921662 | 0.77 | ADRA1A (0.46) | GLP1RADRA1AEPHX2 | |
| SCHEMBL16167789 | 0.77 | ADRA1A (0.46) | GLP1RADRA1AEPHX2 | |
| SCHEMBL16167809 | 0.77 | ADRA1A (0.46) | GLP1RADRA1AEPHX2 | |
| SCHEMBL16167788 | 0.77 | ADRA1A (0.46) | GLP1RADRA1AEPHX2 | |
| SCHEMBL14118030 | 0.77 | ADRA1A (0.46) | GLP1RADRA1AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | GLP1R 5/4885TLR2 1212/4885NMT2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.